Cold Agglutinin Disease Real World Evidence Registry
Active, not recruiting · NCT05791708
Conditions: Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
At a glance
- Research payments reported, 2025
- $122,556
- U.S. investigators named
- 19
- Sites paid
- 20
- Planned or actual enrollment
- 429
About the trial
- Sponsor
- RECORDATI GROUP
- Tested
- Sutimlimab (drug)
- Dates
- Started 2019-12-12; completion 2028-11-02
- Results posted
- Not yet
This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study. Patients with CAD who have been enrolled in previous sutimlimab clinical trials (e.g., BIVV009-01/LTS16214 \[NCT02502903,CAD patients\], BIVV009-03/EFC16215 \[NCT03347396\], and BIVV009-04/EFC16216 \[NCT03347422\]) and who either completed or discontinued the corresponding clinical trial are eligible to participate in the registry.
From ClinicalTrials.gov, last updated 2026-04-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $122,556 in research payments for this study in 2025 (67 payments).
Products named: Enjaymo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Gorgun Akpek, M.D., M.H.S. Hematology & Oncology · San Luis Obispo, CA
- Wei Bai, MD Hematology & Oncology · Santa Maria, CA
- Anthony L. Nguyen, MD Hematology & Oncology · La Jolla, CA
- Catherine M. Broome, MD Hematology & Oncology · Washington, DC
- Rita D. Paschal, MD Hematology & Oncology · Jacksonville, FL
- Trevor Feinstein, M.D. Hematology & Oncology · Fayetteville, GA
- Donald B. Wender, M.D. Hematology & Oncology · Sioux City, IA
- Shivi Jain, M.D. Hematology & Oncology · Chicago, IL
- James J. Rooney, M.D. Hematology & Oncology · Worcester, MA
- Philip Kuriakose, M.D. Internal Medicine · Detroit, MI
- Darla K. Liles, MD Hematology & Oncology · Greenville, NC
- Steven Allen Hematology & Oncology · Lake Success, NY
- Maria Teresa R. Desancho, MD Hematology · New York, NY
- Bernard J. Poiesz, MD Hematology & Oncology · Syracuse, NY
- Kerry A. Rogers, MD Hematology · Columbus, OH
- Aleksandra S. Sander, M.D. Hematology & Oncology · Medford, OR
- Joseph Kiss Specialist · Pittsburgh, PA
- Wahid T. Hanna, MD Hematology · Knoxville, TN
- Livia T. Hegerova, MD Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of California San Diegodispersements $26,460
- Mercy General Hospital, CA $18,283
- Peachtree Neurological Clinic,pc $13,884
- Georgetown University Office of Tech Commercialization $13,209
- Weill Medical College of Cornell University Attn Joint Clinical Trials Office $10,944
- The Feinstein Inst for Medical Research $7,640
- University of Pittsburgh Physicians $4,535
- The Ohio State University Ccicmass Spectrometry and Proteomi Facility $4,337
- University of Alabama Hospital, AL $3,060
- Henry Ford Health Hospital, MI $3,000
- Rush University Medical Center, IL $2,970
- University of Washington Medical Ctr, WA $2,760
- University Clinical Research Dela Llc $2,700
- The Research Found of State University of New York $2,305
- Siouxland Regional Cancer Center $1,920
- Asante $1,612
- University Health System, Inc, TN $1,512
- Reliant Medical Group $744
- East Carolina University Health Hemophilia Treatment Center $351
- Rogue Valley Medical Center $330
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.